Korro initiated with Outperform into 2025 catalysts at Oppenheimer

Oppenheimer initiated coverage of Korro Bio (KRRO) with an Outperform rating and $155 price target The company’s Opera platform enables precise RNA editing via A-to-I editing for genetic diseases by designing customized oligonucleotides with high efficiency, specificity and differentiated delivery to create new functional proteins, the analyst tells investors in a research note. The firm says that with first-inhuman competitor data in October validating RNA editing for alpha-1 antitrypsin deficiency, it likes the “differentiated profile” of Korro’s wholly owned lead candidate KRRO-110, with interim Phase 1/2 data anticipated in the second half of 2025. It anticipates multiple catalysts in the space in 2025 and is a buyer of Korro Bio